Letrozole for Fertility: How It Works and How It Compares to Clomid

How does letrozole stimulate ovulation?

Letrozole belongs to a class of drugs called aromatase inhibitors. Aromatase is an enzyme that converts androgens into estrogen. By temporarily blocking this enzyme for a few days early in the menstrual cycle, letrozole lowers estrogen levels briefly. The pituitary gland — which monitors estrogen — responds to this drop by producing more FSH (follicle-stimulating hormone). The surge in FSH stimulates one or more ovarian follicles to develop, and ovulation typically follows 1Ref 1Legro RS, Brzyski RG, Diamond MP, et al. (2014).Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.Randomized trial (N=750) showing letrozole produced significantly higher live birth rates (27.5% vs 19.1%, p=0.007) and cumulative ovulation rates compared to clomiphene in women with PCOS; mechanism of action of letrozole via aromatase inhibition.

Because the drug is taken for only 5 days (usually days 3–7 or 5–9 of the cycle) and cleared from the body before ovulation, estrogen levels recover naturally before implantation — an advantage over clomiphene, which lingers longer in the system and can cause an anti-estrogenic effect on the uterine lining.

Letrozole vs. Clomid: what does the evidence show?

The most influential trial comparing the two was a large multicenter randomized controlled trial (N=750 women with PCOS who had not previously undergone fertility treatment) 1Ref 1Legro RS, Brzyski RG, Diamond MP, et al. (2014).Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.Randomized trial (N=750) showing letrozole produced significantly higher live birth rates (27.5% vs 19.1%, p=0.007) and cumulative ovulation rates compared to clomiphene in women with PCOS; mechanism of action of letrozole via aromatase inhibition. Key findings:

• Live birth rate: Women taking letrozole had a significantly higher live birth rate compared with clomiphene (27.5% vs. 19.1% cumulative over 5 ovulatory cycles, p=0.007) 1Ref 1Legro RS, Brzyski RG, Diamond MP, et al. (2014).Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.Randomized trial (N=750) showing letrozole produced significantly higher live birth rates (27.5% vs 19.1%, p=0.007) and cumulative ovulation rates compared to clomiphene in women with PCOS; mechanism of action of letrozole via aromatase inhibition.
• Ovulation rate: The cumulative ovulation rate was also meaningfully higher in the letrozole group.
• Multiple pregnancy: Letrozole carries a lower risk of multiple follicle development and therefore a lower risk of twins or higher-order multiples compared with clomiphene.

Based on this evidence, the international PCOS evidence-based guideline now recommends letrozole as first-line pharmacological treatment for ovulation induction in women with PCOS 2Ref 2Teede HJ, Misso ML, Costello MF, et al.; International PCOS Network (2018).Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.International PCOS guideline recommending letrozole as first-line pharmacological agent for ovulation induction in PCOS; dosing guidance and monitoring recommendations. The prior preference for clomiphene has been reversed in most major fertility societies.

What does a letrozole cycle look like?

A typical ovulation induction cycle with letrozole:

1. Baseline ultrasound (day 2–3 of cycle): Your clinician confirms no residual cysts from a prior cycle and that the ovaries are suitable for stimulation. 2. Letrozole taken days 3–7 (or 5–9): Oral pills taken once daily for 5 days. 3. Monitoring ultrasound (around day 10–14): Checks whether a follicle has reached the target size (usually 18–22 mm). 4. Trigger shot (optional): An hCG injection may be used to time ovulation precisely, which is particularly helpful when timed intercourse or IUI is planned. 5. Timed intercourse or IUI: Occurs around the time of confirmed or triggered ovulation. 6. Progesterone support (sometimes): Some clinicians add vaginal or oral progesterone in the second half of the cycle.

Dose adjustments are common — starting doses vary (typically 2.5 mg or 5 mg daily), and your clinician may increase the dose in subsequent cycles if the response is insufficient 2Ref 2Teede HJ, Misso ML, Costello MF, et al.; International PCOS Network (2018).Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.International PCOS guideline recommending letrozole as first-line pharmacological agent for ovulation induction in PCOS; dosing guidance and monitoring recommendations.

What are the common side effects?

Letrozole is generally well tolerated when used for ovulation induction. Common side effects during the 5-day course include 1Ref 1Legro RS, Brzyski RG, Diamond MP, et al. (2014).Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.Randomized trial (N=750) showing letrozole produced significantly higher live birth rates (27.5% vs 19.1%, p=0.007) and cumulative ovulation rates compared to clomiphene in women with PCOS; mechanism of action of letrozole via aromatase inhibition:

• Mild fatigue or dizziness
• Hot flashes (less common than with clomiphene)
• Headache
• Mild nausea
• Mood changes (reported but typically mild)

Because letrozole was originally developed as a breast cancer treatment at much higher doses and longer durations, some patients ask about cancer risk. At the low doses and short courses used for fertility, available evidence has not established a meaningful increased risk of breast or other cancers — but this is a question worth raising with your clinician if you have concerns.

When is letrozole not the right choice?

Letrozole is not appropriate in every situation:

• It does not substitute for IVF when the fallopian tubes are blocked or significantly damaged.
• It is not used in people who already ovulate regularly (it is indicated for ovulatory dysfunction).
• It requires monitoring to ensure response is appropriate — multiple follicle development raises the risk of twins or triplets, which carries health risks for both the pregnant person and babies 3Ref 3Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology (2017).Guidance on the limits to the number of embryos to transfer: a committee opinion.Context on multiple pregnancy risk from multiple follicle development during ovulation induction and the health risks of multiple gestations.
• It is not indicated during pregnancy; if there is any possibility of pregnancy, testing is done before starting each cycle.

Your reproductive endocrinologist will confirm whether letrozole is appropriate for your specific situation.